AstraZeneca joins the weight loss drug race: oral medication reduces weight by 11.8%
```
AstraZeneca Enters the Oral Obesity Drug Market: Its Investigational Drug Elecoglipron Shows Mid-stage Trial Data Indicating 11.8% Weight Loss. Although the weight loss is less than Eli Lilly’s, AstraZeneca positions itself as a strong competitor in this rapidly growing market thanks to a lower dropout rate due to